Literature DB >> 15925702

Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion.

Carmen Aragón1, Beatriz López-Corcuera.   

Abstract

The functions of the high-affinity glycine transporters (GLYTs) in vivo have been revealed recently using gene-deletion studies. Results from studies of homozygous knockout mice have reinforced the idea that GLYTs might be specific clinical targets to modulate inhibitory glycine-mediated neurotransmission. In addition, molecular and behavioural analysis of heterozygous mice has confirmed the therapeutic potential of GLYT1 inhibitors in the treatment of several neurological and psychiatric disorders.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15925702     DOI： 10.1016/j.tips.2005.04.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  30 in total

Review 1.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

3.  Intact working memory in the absence of forebrain neuronal glycine transporter 1.

Authors:  Sylvain Dubroqua; Lucas Serrano; Detlev Boison; Joram Feldon; Pascual A Gargiulo; Benjamin K Yee
Journal:  Behav Brain Res       Date:  2012-02-08       Impact factor: 3.332

4.  Brief embryonic strychnine exposure in zebrafish causes long-term adult behavioral impairment with indications of embryonic synaptic changes.

Authors:  Nicole M Roy; Brianna Arpie; Joseph Lugo; Elwood Linney; Edward D Levin; Daniel Cerutti
Journal:  Neurotoxicol Teratol       Date:  2012-08-07       Impact factor: 3.763

5.  Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.

Authors:  Deepak Cyril D'Souza; Nagendra Singh; Jacqueline Elander; Michelle Carbuto; Brian Pittman; Joanna Udo de Haes; Magnus Sjogren; Pierre Peeters; Mohini Ranganathan; Jacques Schipper
Journal:  Neuropsychopharmacology       Date:  2011-11-23       Impact factor: 7.853

6.  Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

Authors:  Santiago Bullich; Mark Slifstein; Jan Passchier; N Venkatesha Murthy; Lawrence S Kegeles; Jong-Hoon Kim; Xiaoyan Xu; Roger N Gunn; Raul Herance; Juan Domingo Gispert; Antonio Gutiérrez; Magí Farré; Marc Laruelle; Ana M Catafau
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

7.  Molecular basis of the dominant negative effect of a glycine transporter 2 mutation associated with hyperekplexia.

Authors:  Esther Arribas-González; Jaime de Juan-Sanz; Carmen Aragón; Beatriz López-Corcuera
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

8.  Presynaptic control of glycine transporter 2 (GlyT2) by physical and functional association with plasma membrane Ca2+-ATPase (PMCA) and Na+-Ca2+ exchanger (NCX).

Authors:  Jaime de Juan-Sanz; Enrique Núñez; Francisco Zafra; María Berrocal; Isaac Corbacho; Ignacio Ibáñez; Esther Arribas-González; Daniel Marcos; Beatriz López-Corcuera; Ana M Mata; Carmen Aragón
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

Review 9.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors:  Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Behav Neurosci       Date:  2009-10       Impact factor: 1.912
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.